From: Psychotropic drugs and the risk of fractures in old age: a prospective population-based study
Drug | Number of fracture cases No. (%)/controls No. (%) | Univariate analysis | Age-adjusted analysis | Adjusted analysisa | |||
---|---|---|---|---|---|---|---|
 |  | RR (95% CI) | P-value | RR (95% CI) | P-value | RR (95% CI) | P-value |
3-year follow-up | |||||||
One BZD | 7 (9.2)/20 (5.7) | 1.7 (0.7-4.1) | .21 | 1.4 (0.6-3.4) | .44 | - | - |
One AP | 2 (6.5)/20 (5.7) | 1.3 (0.3-5.4) | .76 | 0.9 (0.2-4.1) | .93 | - | - |
One AD | 1 (7.1)/20 (5.7) | 1.3 (0.2-9.5) | .81 | 1.0 (0.1-7.9) | .97 | - | - |
Two or more BZDs | 3 (23.1)/20 (5.7) | 4.9 (1.4-16.4) | .01 | 4.7 (1.4-15.7) | .01 | 4.7 (1.4-16.3) | .01 |
Two or more APs | 1 (20.0)/20 (5.7) | 7.0 (0.9-52.0) | .06 | 9.4 (1.2-71.1) | .03 | 8.3 (1.0-66.2) | .05 |
Two or more ADs | 0 (0.0)/20 (5.7) | - | - | - | - | - | - |
BZD and APb | 2 (10.5)/20 (5.7) | 2.3 (0.5 - 9.8) | .27 | 2.5 (0.8-8.4) | .13 | - | - |
BZD and ADb | 1 (10.0)/20 (5.7) | 1.9 (0.3-14.2) | .53 | 1.5 (0.2-11.3) | .67 | - | - |
AP and ADb | 1 (20.0)/20 (5.7) | 4.9 (0.7-36.6) | .12 | 4.9 (0.7-36.0) | .12 | - | - |
6-year follow-up | |||||||
One BZD | 11 (14.5)/29 (8.3) | 2.1 (1.1-4.3) | .03 | 1.8 (0.9-3.7) | .09 | - | - |
One AP | 4 (12.9)/29 (8.3) | 2.0 (0.7-5.6) | .20 | 1.6 (0.6-4.8) | .37 | - | - |
One AD | 1 (7.1)/29 (8.3) | 1.0 (0.1-7.1) | .98 | 0.9 (0.1-6.6) | .91 | - | - |
Two or more BZDs | 4 (30.8)/29 (8.3) | 5.5 (1.9-15.8) | .001 | 5.7 (2.0-16.2) | .001 | 5.8 (2.0-16.6) | .001 |
Two or more APs | 1 (20.0)/29 (8.3) | 6.2 (0.8-45.5) | .07 | 7.6 (1.0-56.7) | .05 | 7.9 (1.1-59.0) | .04 |
Two or more ADs | 0 (0.0)/29 (8.3) | - | - | - | - | - | - |
BZD and APb | 3 (15.8)/29 (8.3) | 2.8 (0.7-9.3) | .09 | 2.5 (0.8-8.4) | .13 | - | - |
BZD and ADb | 1 (10.0)/29 (8.3) | 1.6 (0.2-11.8) | .64 | 1.5 (0.2-11.3) | .67 | - | - |
AP and ADb | 1 (20.0)/29 (8.3) | 4.8 (0.7-35.5) | .12 | 4.9 (0.7-36.0) | .12 | - | - |